Alfadex

Alfadex

SCHEMBL181370

OCC1OC2OC3C(CO)OC(OC4C(CO)OC(OC5C(CO)OC(OC6C(CO)OC(OC7C(CO)OC(OC1C(O)C2O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 1.00
TSHR P16473 2/20 1.00
LMNA P02545 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
TXNRD1 Q16881 6/20 0.77
TXNRD3 Q86VQ6 6/20 0.77
TXNRD2 Q9NNW7 6/20 0.77
HDAC3 O15379 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
FYN P06241 1/20 0.47
MAOA P21397 1/20 0.47
SLC6A2 P23975 1/20 0.47
HTR2C P28335 1/20 0.47
HTR2B P41595 1/20 0.47
SLC6A3 Q01959 1/20 0.47
LGALS1 P09382 2/20 0.37
LGALS3 P17931 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alfadex SCHEMBL21134960 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNATDP1TXNRD1
Gamma-Cyclodextrin SCHEMBL25455463 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNATDP1TXNRD1
Betadex SCHEMBL24109285 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNATDP1TXNRD1
Gamma-Cyclodextrin SCHEMBL20533920 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNATDP1TXNRD1
Gamma-Cyclodextrin SCHEMBL25455531 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNATDP1TXNRD1
Alfadex SCHEMBL23188277 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNATDP1TXNRD1
Alfadex SCHEMBL24109286 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNATDP1TXNRD1
Alfadex SCHEMBL25455476 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNATDP1TXNRD1
Betadex SCHEMBL23188251 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNATDP1TXNRD1
Gamma-Cyclodextrin SCHEMBL20998969 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNATDP1TXNRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025137451-A1 APPARATUS AND METHOD FOR DETECTION OF METAL IONS AND PEAS POLLUTANTS IN A SAMPLE 12-15 MOLECULAR DIAGNOSTICS, INC. (US) 2025-06-26 WO claimed
US-10851469-B2 Synthesis of core-shell nanoparticles and applications of said nanoparticles for surface enhanced Raman scattering UNIVERSITE PARIS DIDEROT (FR) 2020-12-01 US claimed
EP-3526375-B1 SYNTHESIS OF CORE-SHELL NANOPARTICLES AND USES OF SAID NANOPARTICLES FOR SURFACE-ENHANCED RAMAN SPECTROSCOPY UNIV PARIS DIDEROT (FR) 2020-06-24 EP claimed
US-20200048788-A1 SYNTHESIS OF CORE-SHELL NANOPARTICLES AND APPLICATIONS OF SAID NANOPARTICLES FOR SURFACE ENHANCED RAMAN SCATTERING UNIVERSITE PARIS DIDEROT (FR) 2020-02-13 US claimed
EP-3526375-A1 SYNTHESIS OF CORE-SHELL NANOPARTICLES AND USES OF SAID NANOPARTICLES FOR SURFACE-ENHANCED RAMAN SPECTROSCOPY Université Paris Diderot (FR) 2019-08-21 EP claimed
US-8435966-B2 Associations of xanthogenates and cyclodextrins, and their use BIOSPHINGS AG (DE) 2013-05-07 US claimed
US-20100240606-A1 ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE BIOSPHINGS AG (DE) 2010-09-23 US claimed
CN-101522612-A Associations of xanthogenates and cyclodextrins, and their use BIOSPHINGS AG (DE) 2009-09-02 CN claimed
EP-2001840-A1 ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE BioSphings AG (DE) 2008-12-17 EP claimed
WO-2007112828-A1 ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE BIOSPHINGS AG (DE) 2007-10-11 WO claimed
US-20260137805-A1 SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY Oculis Operations Sàrl (CH) 2026-05-21 US disclosed
EP-4391840-B1 MEDICAL LIQUID COMPOSITION FOR AERIAL ADMINISTRATION NATURAL ACAD S R L (IT) 2026-05-06 EP disclosed
US-12610957-B2 Compositions and methods of controlling pests PERTINENT ECO-SOLUTIONS INC. (US) 2026-04-28 US disclosed
US-12551475-B2 Methods and compositions for treating RNA viral infections MODEL MEDICINES, INC. (US) 2026-02-17 US disclosed
EP-4687838-A2 UNIT DOSAGE COMPOSITION COMPRISING MIDAZOLAM B. Braun Melsungen AG (DE) 2026-02-11 EP disclosed
US-20070092544-A1 Natural insect repellant INT'L ALLY, INC. 2007-04-26 US disclosed
US-20070088508-A1 Cocrystallization methods APTUIT (WEST LAFAYETTE), LLC 2007-04-19 US disclosed
US-20070049496-A1 LIMONENE-CONTAINING HERBICIDE COMPOSITIONS, HERBICIDE CONCENTRATE FORMULATIONS AND METHODS FOR MAKING AND USING SAME FOR ORGANIC PRODUCTION AVENGER PRODUCTS, LLC 2007-03-01 US disclosed
US-6824707-B2 MIXTURE CONTAINING DOPE CLARIANT INTERNATIONAL LTD. (CH) 2004-11-30 US disclosed
US-20030127627-A1 Active matrix liquid crystal device and smectic liquid crystal mixture CLARIANT INTERNATIONAL LTD. 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137805-A1 SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY CFD, PDE6D, PDE6H ALDH1A1 4332/4885TSHR 3138/4885LMNA 3427/4885
US-12551475-B2 Methods and compositions for treating RNA viral infections SARS1, EIF2AK2, SNRPE ALDH1A1 2656/4885TSHR 1607/4885LMNA 1401/4885
US-12610957-B2 Compositions and methods of controlling pests DGAT2, DGAT1, DAGLB ALDH1A1 2856/4885TSHR 3322/4885LMNA 611/4885
US-20100240606-A1 ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE HLA-DRB1, CXCR3, ANTXR2 ALDH1A1 4475/4885TSHR 2243/4885LMNA 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.